- Zhifei Biological reported a net income of 2.02 billion yuan for the fiscal year, falling short of the estimated 2.47 billion yuan.
- Fiscal year revenue came in at 26.07 billion yuan, below the expected 28.27 billion yuan.
- Research and Development (R&D) expenses totaled 971.4 million yuan, slightly under the projected 993.5 million yuan.
- Selling and marketing expenses were 2.65 billion yuan, significantly lower than the anticipated 3.39 billion yuan.
- In the first quarter, Zhifei Biological experienced a net loss of 305.1 million yuan with revenue of 2.37 billion yuan.
- Analyst recommendations for Zhifei Biological include 14 “buy” ratings, 3 “hold” ratings, and no “sell” ratings.
A look at Chongqing Zhifei Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Chongqing Zhifei Biological Products Company Ltd. has been rated using Smartkarma Smart Scores, providing an insight into its long-term prospects. The company excels in dividend payouts, receiving a top score of 5, showcasing its commitment to rewarding shareholders. With a strong emphasis on value at 4, Chongqing Zhifei Biological Products offers investors the potential for solid returns relative to its intrinsic worth. While growth and resilience scores stand at 3, indicating steady progress and adaptability to challenges, momentum lags slightly at 2, suggesting a slower pace of market traction.
Specializing in vaccines and biological products, Chongqing Zhifei Biological Products Company Ltd. focuses on a range of essential healthcare offerings such as prevention products, blood products, diagnostic reagents, and therapeutic agents. This broad portfolio underscores the company’s dedication to advancing public health through innovative solutions. With an overall positive outlook based on Smartkarma Smart Scores, Chongqing Zhifei Biological Products demonstrates a strong foundation for continued success in the biotechnology industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
